17-02-2022 дата публикации
Номер: US20220049004A1
Принадлежит:
The present invention provides an engineered immune cell targeting BCMA and use thereof. In particular, the present invention provides a CAR specifically targeting BCMA, the CAR comprising an antigen-binding domain which is an S-derived scFv, an antibody heavy chain variable region as shown in SEQ ID NO: 9 and an antibody light chain variable region as shown in SEQ ID NO: 10. The present invention also provides a CAR-T cell comprising the CAR, a double CAR- and CAR-T cell comprising the S-derived scFv, and related use thereof. Compared to CAR-T cells constructed using other scFvs, the constructed CAR-T cell of the present invention has a better killing effect and tumor elimination capability. 1. A chimeric antigen receptor (CAR) , an antigen binding domain (scFv) of which comprises an antibody heavy chain variable region as shown in SEQ ID NO: 9 and an antibody light chain variable region as shown in SEQ ID NO: 10.2. The CAR according to claim 1 , wherein the scFv is as shown in the following formula A or formula B:{'br': None, 'sub': ['H', 'L'], '#text': 'V-V,\u2003\u2003(A);'}{'br': None, 'sub': ['L', 'H'], '#text': 'V-V,\u2003\u2003(B)'}{'sub': ['H', 'L'], '#text': 'in the formula, Vis the antibody heavy chain variable region; Vis the antibody light chain variable region; and “-” is a linker peptide or a peptide bond.'}3. A bispecific CAR claim 1 , which targets BCMA and a first target claim 1 ,wherein an antigen binding domain (scFv) targeting the BCMA in the bispecific CAR comprises an antibody heavy chain variable region as shown in SEQ ID NO: 9 and an antibody light chain variable region as shown in SEQ ID NO: 10; andthe first target is selected from the group consisting of:CD138, Kappa Light Chain, NKG2D-ligands, TACI, GPRC5D, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD38, CD40, CD44V6, CD47, CD52, CD56, CD57, CD58, CD79b, CD80, CD86, CD81, CD123, CD133, CD137, CD151, CD171, CD276, CLL1, B7H4, BCMA, VEGFR-2, EGFR, GPC3, PMSA, ...
Подробнее